The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Castle Biosciences Inc (NASDAQ: CSTL) closed at $21.27 down -1.89% from its previous closing price of $21.68. In other words, the price has decreased by -$1.89 from its previous closing price. On the day, 0.55 million shares were traded.
Ratios:
For a deeper understanding of Castle Biosciences Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.07 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.03. For the most recent quarter (mrq), Quick Ratio is recorded 7.13 and its Current Ratio is at 7.29. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on December 14, 2023, initiated with a Buy rating and assigned the stock a target price of $25.
On January 05, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $54.
On January 07, 2022, Stephens started tracking the stock assigning a Overweight rating and target price of $59.Stephens initiated its Overweight rating on January 07, 2022, with a $59 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 20 ’25 when Stokes Frank sold 8,046 shares for $26.70 per share. The transaction valued at 214,828 led to the insider holds 35,319 shares of the business.
BRADBURY DANIEL sold 7,867 shares of CSTL for $221,637 on Feb 05 ’25. The Director now owns 0 shares after completing the transaction at $28.17 per share. On Feb 05 ’25, another insider, Daniel Bradbury, who serves as the Officer of the company, bought 7,867 shares for $28.12 each.
Valuation Measures:
As of this moment, Castle’s Price-to-Earnings (P/E) ratio for their current fiscal year is 34.70. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.83 while its Price-to-Book (P/B) ratio in mrq is 1.33.
Stock Price History:
Over the past 52 weeks, CSTL has reached a high of $35.84, while it has fallen to a 52-week low of $16.97. The 50-Day Moving Average of the stock is -21.40%, while the 200-Day Moving Average is calculated to be -21.23%.
Shares Statistics:
A total of 28.48M shares are outstanding, with a floating share count of 27.66M. Insiders hold about 2.98% of the company’s shares, while institutions hold 97.23% stake in the company.
Earnings Estimates
The dynamic stock of Castle Biosciences Inc (CSTL) is currently being evaluated by a team of 7.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.23 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.09 and -$1.67 for the fiscal current year, implying an average EPS of -$1.44. EPS for the following year is -$1.79, with 7.0 analysts recommending between -$1.02 and -$2.62.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $80.02M this quarter.It ranges from a high estimate of $85.25M to a low estimate of $69.2M. As of the current estimate, Castle Biosciences Inc’s year-ago sales were $72.97MFor the next quarter, 7 analysts are estimating revenue of $71.61M. There is a high estimate of $73.09M for the next quarter, whereas the lowest estimate is $69.5M.
A total of 7 analysts have provided revenue estimates for CSTL’s current fiscal year. The highest revenue estimate was $291.2M, while the lowest revenue estimate was $283.9M, resulting in an average revenue estimate of $287.9M. In the same quarter a year ago, actual revenue was $219.79MBased on 7 analysts’ estimates, the company’s revenue will be $296.84M in the next fiscal year. The high estimate is $312.8M and the low estimate is $275.4M.
